Researcher.Life Logo

Antiviral Therapy : Impact Factor & More

eISSN: 2040-2058pISSN: 1359-6535

Aims and Scope of Antiviral Therapy

Antiviral Therapy is a peer-reviewed medical journal published by International Medical Press. It publishes primary papers and reviews on all aspects of the clinical development of antiviral drugs, including clinical trial results, drug resistance, viral diagnostics, drug safety, pharmacoepidemiology, and vaccines. Antiviral Therapy is an official publication of the International Society for Antiviral Research. Less

Key Metrics

CiteScore
5.1
Impact Factor
< 5
SJR
Q2Pharmacology
SNIP
0.62
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Antiviral Therapy

Antiviral Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher SAGE PUBLICATIONS LTD
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year1996
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Antiviral Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Antiviral Therapy

Harnessing SuperNatural database to identify VP35 inhibitors as anti-Ebola drug candidates: A multistage In silico study.
  • 1 Dec 2025
  • Antiviral therapy
Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection.
  • 1 Dec 2025
  • Antiviral therapy
A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants.
  • 1 Dec 2025
  • Antiviral therapy
Pharmacokinetic and mass balance characterization of [14C] RAY1216, a SARS-CoV-2 Mpro inhibitor, in healthy Chinese male subjects.
  • 1 Oct 2025
  • Antiviral therapy
Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report.
  • 1 Oct 2025
  • Antiviral therapy
Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines.
  • 29 Sep 2025
  • Antiviral therapy
Harnessing SuperNatural database to identify VP35 inhibitors as anti-Ebola drug candidates: A multistage In silico study.
  • 1 Dec 2025
  • Antiviral therapy
Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection.
  • 1 Dec 2025
  • Antiviral therapy
A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants.
  • 1 Dec 2025
  • Antiviral therapy
Pharmacokinetic and mass balance characterization of [14C] RAY1216, a SARS-CoV-2 Mpro inhibitor, in healthy Chinese male subjects.
  • 1 Oct 2025
  • Antiviral therapy
Enterovirus-associated deafness and myositis in an immunocompromised patient with in vivo and in vitro efficacy of intravenous immunoglobulins and remdesivir: Case report.
  • 1 Oct 2025
  • Antiviral therapy
Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines.
  • 29 Sep 2025
  • Antiviral therapy

FAQs on Antiviral Therapy